Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

XNCR

Xencor Inc

Dec 20 • 04:00PM ET

24.13

Dollar change +0.12
Percentage change 0.50	%

Healthcare • Biotechnology • USA • NASD

Peers: REGN VRTX BIIB ALNY INCY BLUE SGMO FGEN PGEN ADAP

| Held by: IJR VTI IWM VB VXF VBK XBI SPSM IBB IJS

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.20	Insider Own	5.87%	Shs Outstand	69.96M	Perf Week	0.42%
Market Cap	1.70B	Forward P/E	-	EPS next Y	-3.13	Insider Trans	-4.33%	Shs Float	65.87M	Perf Month	1.73%
Income	-198.24M	PEG	-	EPS next Q	-0.78	Inst Own	98.81%	Short Float	6.77%	Perf Quarter	18.98%
Sales	85.16M	P/S	19.93	EPS this Y	-76.84%	Inst Trans	18.38%	Short Ratio	8.10	Perf Half Y	20.11%
Book/sh	10.35	P/B	2.33	EPS next Y	14.77%	ROA	-22.50%	Short Interest	4.46M	Perf Year	18.40%
Cash/sh	7.72	P/C	3.13	EPS next 5Y	-	ROE	-28.47%	52W Range	15.31 - 27.24	Perf YTD	13.66%
Dividend Est.	-	P/FCF	58.16	EPS past 5Y	-9.81%	ROI	-24.76%	52W High	-11.42%	Beta	0.71
Dividend TTM	-	Quick Ratio	6.23	Sales past 5Y	70.11%	Gross Margin	85.51%	52W Low	57.61%	ATR (14)	1.15
Dividend Ex-Date	-	Current Ratio	6.23	EPS Y/Y TTM	-61.20%	Oper. Margin	-253.73%	RSI (14)	48.03	Volatility	6.74% 4.39%
Employees	280	Debt/Eq	0.12	Sales Y/Y TTM	-41.37%	Profit Margin	-232.77%	Recom	1.33	Target Price	32.91
Option/Short	Yes / Yes	LT Debt/Eq	0.11	EPS Q/Q	-76.14%	Payout	-	Rel Volume	7.71	Prev Close	24.01
Sales Surprise	-26.61%	EPS Surprise	27.65%	Sales Q/Q	-81.90%	Earnings	Nov 06 AMC	Avg Volume	550.92K	Price	24.13
SMA20	-4.22%	SMA50	3.25%	SMA200	14.36%	Trades		Volume	4,248,554	Change	0.50%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-12-24	Initiated	Wells Fargo	Overweight	$37
Dec-02-24	Upgrade	Piper Sandler	Neutral → Overweight	$20 → $30
Apr-16-24	Reiterated	BTIG Research	Buy	$56 → $38
Feb-28-24	Downgrade	Piper Sandler	Overweight → Neutral	$37 → $24
May-19-23	Initiated	BofA Securities	Buy	$42
Dec-06-22	Initiated	Cowen	Outperform
Oct-13-22	Upgrade	Raymond James	Outperform → Strong Buy	$58
Sep-21-22	Initiated	JP Morgan	Overweight	$37
Jul-06-22	Resumed	Canaccord Genuity	Buy	$50
Feb-11-22	Initiated	BMO Capital Markets	Outperform	$54
Jan-21-22	Initiated	SMBC Nikko	Outperform	$60
Dec-15-21	Initiated	H.C. Wainwright	Buy	$61
Oct-15-21	Resumed	BTIG Research	Buy	$56
Feb-24-21	Upgrade	Raymond James	Mkt Perform → Outperform	$58
Mar-04-20	Initiated	Barclays	Underweight	$28
Feb-25-20	Upgrade	Guggenheim	Neutral → Buy	$43
Jan-30-20	Initiated	RBC Capital Mkts	Outperform	$44
Nov-20-19	Resumed	Guggenheim	Neutral
Aug-07-19	Downgrade	Raymond James	Outperform → Mkt Perform
Aug-07-19	Downgrade	Guggenheim	Buy → Neutral

Show Previous Ratings

Dec-12-24 12:00PM	All You Need to Know About Xencor (XNCR) Rating Upgrade to Buy (Zacks)
Dec-04-24 09:55AM	Wall Street Analysts Think Xencor (XNCR) Could Surge 31.58%: Read This Before Placing a Bet (Zacks)
Nov-26-24 04:01PM	Xencor to Participate at Upcoming Investor Conferences (Business Wire)
Nov-18-24 09:55AM	Wall Street Analysts Believe Xencor (XNCR) Could Rally 53.53%: Here's is How to Trade (Zacks)
Nov-14-24 09:55AM	Xencor (XNCR)'s Technical Outlook is Bright After Key Golden Cross (Zacks)
05:15PM	Loading…
Nov-06-24 05:15PM	Xencor (XNCR) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +5.39%
04:11PM	Xencor: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Xencor Reports Third Quarter 2024 Financial Results (Business Wire)
Nov-04-24 07:00AM	Xencor Doses First Subject in Phase 1/2 Study of XmAb942 in Development for Patients with Inflammatory Bowel Disease (Business Wire)
Nov-01-24 09:55AM	Does Xencor (XNCR) Have the Potential to Rally 68.16% as Wall Street Analysts Expect? (Zacks)
Oct-29-24 10:01AM	Xencor (XNCR) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-18-24 03:05PM	State Street Corp's Strategic Reduction in Xencor Inc Holdings (GuruFocus.com)
Oct-16-24 09:55AM	Wall Street Analysts Predict a 67.2% Upside in Xencor (XNCR): Here's What You Should Know (Zacks)
Oct-10-24 08:09AM	Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases (Business Wire)
Oct-04-24 08:01AM	Xencor Announces Upcoming Change to Board of Directors (Business Wire)
04:01PM	Loading…
Sep-12-24 04:01PM	Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (Business Wire)
04:55AM	Xencor (XNCR) Surges 10.5%: Is This an Indication of Further Gains? (Zacks)
Sep-11-24 06:31AM	Xencor Announces Pricing of $175 Million Public Offering of Common Stock (Business Wire) +10.45%
Sep-10-24 04:01PM	Xencor Announces Proposed Public Offering of Common Stock (Business Wire)
Sep-09-24 07:31AM	Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs (Business Wire) +22.93%
Sep-06-24 08:01AM	Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024 (Business Wire)
Aug-05-24 09:55PM	XNCR Stock Earnings: Xencor Misses EPS, Beats Revenue for Q2 2024 (InvestorPlace) -7.30%
05:15PM	Xencor (XNCR) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:12PM	Xencor: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Xencor Reports Second Quarter 2024 Financial Results (Business Wire)
Jun-13-24 08:01AM	Xencor Regains CD20 x CD3 Bispecific T-Cell Engager (Business Wire)
May-10-24 01:45PM	Xencor Inc (XNCR) Q1 2024 Earnings: Misses Revenue and Earnings Estimates (GuruFocus.com)
06:20AM	Wedbush Adjusts Xencor's Price Target to $36 From $34, Keeps Outperform Rating (MT Newswires)
May-09-24 11:54PM	XNCR Stock Earnings: Xencor Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
05:18PM	Xencor: Q1 Earnings Snapshot (Associated Press Finance)
04:09PM	Loading…
04:09PM	Xencor Reports First Quarter 2024 Financial Results (Business Wire)
May-06-24 10:00AM	Xencor (XNCR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
May-03-24 07:01PM	Insider Sale at Xencor Inc (XNCR): EVP, Chief Development Officer Nancy Valente Sells Shares (GuruFocus.com)
May-02-24 03:31AM	Xencor (XNCR) Moves 14.3% Higher: Will This Strength Last? (Zacks)
Apr-09-24 08:01AM	Xencor Appoints Bart Cornelissen as Chief Financial Officer (Business Wire)
Mar-08-24 05:01PM	Insider Sell: SR. VICE PRESIDENT & CFO John Kuch Sells 4,474 Shares of Xencor Inc (XNCR) (GuruFocus.com)
Mar-07-24 05:00PM	Insider Sell: President & CEO Bassil Dahiyat Sells 12,528 Shares of Xencor Inc (XNCR) (GuruFocus.com)
Feb-28-24 04:01PM	Xencor to Present at Upcoming Investor Conferences (Business Wire) -14.06%
09:35AM	Q4 2023 Xencor Inc Earnings Call (Thomson Reuters StreetEvents)
08:38AM	Xencor, Inc. (NASDAQ:XNCR) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-27-24 05:20PM	Xencor (XNCR) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:39PM	Xencor Inc (XNCR) Reports Mixed Financial Results for Q4 and Full Year 2023 (GuruFocus.com)
04:26PM	Xencor: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Xencor Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
Feb-20-24 04:31PM	Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update (Business Wire)
Feb-19-24 03:37AM	Xencor (XNCR) Surges 13.4%: Is This an Indication of Further Gains? (Zacks)
Feb-15-24 10:00AM	Xencor (XNCR) Earnings Expected to Grow: What to Know Ahead of Q4 Release (Zacks) +5.97%
Jan-03-24 04:01PM	Xencor to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
09:55AM	Xencor (XNCR) Soars 6.0%: Is Further Upside Left in the Stock? (Zacks)
Jan-02-24 08:01AM	Dane Leone Joins Xencor as Senior Vice President, Corporate Strategy (Business Wire) +6.03%
Dec-30-23 05:02PM	Insider Sell: Xencor Inc President & CEO Bassil Dahiyat Sells 45,000 Shares (GuruFocus.com)
Nov-21-23 04:01PM	Xencor to Present at the Piper Sandler 35th Annual Healthcare Conference (Business Wire) -6.99%
Nov-09-23 02:19PM	Xencor, Inc. (NASDAQ:XNCR) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 05:21AM	Xencor pulls back from Genentech cancer pact to cut costs, as CytomX drops ex-AbbVie ADC (FierceBiotech.com) -7.01%
Nov-07-23 04:39PM	Xencor: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Xencor Sells Portion of Royalties and Milestones from Ultomiris and Monjuvi to OMERS Life Sciences for $215 Million (Business Wire)
04:01PM	Xencor Reports Third Quarter 2023 Financial Results (Business Wire)
Nov-03-23 12:01PM	Xencor Presents Preclinical Data from Multiple XmAb Research Programs at the SITC Annual Meeting (Business Wire) +5.49%
Oct-31-23 04:01PM	Xencor to Host Third Quarter 2023 Financial Results Webcast and Conference Call on November 7, 2023 (Business Wire)
12:00PM	Xencor (XNCR) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Oct-26-23 08:01AM	Xencor Announces Planned Retirement of Chief Financial Officer John Kuch (Business Wire)
Oct-17-23 04:21AM	Jazz (JAZZ) Soars 5.3%: Is Further Upside Left in the Stock? (Zacks)
Sep-27-23 09:01AM	Xencor to Present Multiple Posters at the SITC Annual Meeting (Business Wire)
Sep-19-23 04:01PM	Xencor Appoints Barbara J. Klencke, M.D., to Board of Directors (Business Wire)
Aug-08-23 06:01AM	Analysts Just Published A Bright New Outlook For Xencor, Inc.'s (NASDAQ:XNCR) (Simply Wall St.)
Aug-07-23 04:02PM	Xencor, Inc. (NASDAQ:XNCR) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-03-23 05:15PM	Xencor (XNCR) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:13PM	Xencor: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Xencor Reports Second Quarter 2023 Financial Results (Business Wire)
Jul-27-23 08:01AM	Xencor to Host Second Quarter 2023 Financial Results Webcast and Conference Call on August 3, 2023 (Business Wire)
Jul-03-23 08:38PM	7 Battered Stocks That Could TRIPLE by 2024 (InvestorPlace)
Jun-21-23 08:00PM	XNCR: Lowering target price to $27.00 (Argus Research)
Jun-18-23 10:00AM	Investors in Xencor (NASDAQ:XNCR) have unfortunately lost 34% over the last five years (Simply Wall St.)
May-30-23 06:01PM	Xencor Presents Clinical Results from Phase 1a Study of XmAb®564 at the EULAR 2023 Congress (Business Wire)
May-09-23 01:49PM	Q1 2023 Xencor Inc Earnings Call (Thomson Reuters StreetEvents)
May-08-23 05:15PM	Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:08PM	Xencor: Q1 Earnings Snapshot (AP Finance)
04:01PM	Xencor Reports First Quarter 2023 Financial Results (Business Wire)
May-01-23 04:01PM	Xencor to Host First Quarter 2023 Financial Results Webcast and Conference Call on May 8, 2023 (Business Wire)
Apr-26-23 08:00PM	XNCR: Lowering target price to $28.00 (Argus Research)
08:01AM	Xencor Appoints Nancy Valente, M.D., as Chief Development Officer (Business Wire)
Apr-17-23 01:31PM	Xencor Highlights CD28 Bispecific Antibody Platform at AACR Annual Meeting 2023 (Business Wire)
Apr-09-23 01:19PM	7 Biotech Stocks to Buy for 100% Returns (InvestorPlace)
Mar-14-23 04:31PM	Xencor to Present Preclinical Data from Novel XmAb® CD28 Bispecific Antibody Programs at the American Association for Cancer Research Annual Meeting 2023 (Business Wire)
02:56AM	Strength Seen in Xencor (XNCR): Can Its 5.3% Jump Turn into More Strength? (Zacks)
Feb-28-23 05:10AM	Xencor, Inc. (NASDAQ:XNCR) Analysts Just Trimmed Their Revenue Forecasts By 13% (Simply Wall St.)
Feb-25-23 07:17AM	Xencor Full Year 2022 Earnings: EPS Beats Expectations (Simply Wall St.)
Feb-23-23 05:25PM	Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Xencor Reports Fourth Quarter and Full Year 2022 Financial Results (Business Wire)
Feb-20-23 10:00AM	FibroGen (FGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
Feb-16-23 04:01PM	Xencor to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023 (Business Wire)
Feb-07-23 04:01PM	Xencor to Present at the SVB Securities Global Biopharma Conference (Business Wire)
Jan-26-23 02:33PM	Why Shares of Zencor Rose This Week (Motley Fool)
Jan-09-23 08:01AM	Xencor Highlights 2023 Corporate Priorities and Provides Portfolio Updates (Business Wire)
Jan-05-23 06:30AM	Caris Life Sciences and Xencor Expand Target Discovery Collaboration for Novel XmAb® Antibody Drug Candidates (PR Newswire)
Jan-04-23 04:01PM	Xencor to Present at the 41st Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-12-22 03:44PM	12 Best Small-Cap Healthcare Stocks To Buy Now (Insider Monkey)
10:00AM	Xencor Presents Data from Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin Lymphoma at the American Society of Hematology Annual Meeting (Business Wire)
Nov-30-22 09:55AM	Does Xencor (XNCR) Have the Potential to Rally 69% as Wall Street Analysts Expect? (Zacks)
Nov-25-22 12:00PM	Xencor (XNCR) Upgraded to Buy: Here's What You Should Know (Zacks)

Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Montgomery Alan Bruce	Director	Dec 02 '24	Option Exercise	17.10	13,301	227,458	22,441	Dec 04 06:08 PM
Montgomery Alan Bruce	Director	Dec 04 '24	Option Exercise	16.76	1,421	23,812	10,561	Dec 04 06:08 PM
Montgomery Alan Bruce	Director	Dec 02 '24	Sale	27.03	13,301	359,525	9,140	Dec 04 06:08 PM
Montgomery Alan Bruce	Director	Dec 04 '24	Sale	27.03	1,421	38,406	9,140	Dec 04 06:08 PM
Montgomery Alan Bruce	Director	Dec 04 '24	Proposed Sale	27.03	1,421	38,406		Dec 04 04:10 PM
Montgomery Alan Bruce	Director	Dec 02 '24	Proposed Sale	27.03	13,301	359,525		Dec 02 04:53 PM
Dahiyat Bassil I	PRESIDENT & CEO	Nov 21 '24	Option Exercise	15.69	49,278	773,172	401,893	Nov 25 04:04 PM
Dahiyat Bassil I	PRESIDENT & CEO	Nov 22 '24	Option Exercise	15.69	13,548	212,568	366,163	Nov 25 04:04 PM
Dahiyat Bassil I	PRESIDENT & CEO	Nov 21 '24	Sale	24.07	49,278	1,186,363	352,615	Nov 25 04:04 PM
Dahiyat Bassil I	Officer	Nov 21 '24	Proposed Sale	24.07	49,278	1,186,362		Nov 21 04:21 PM
Dahiyat Bassil I	PRESIDENT & CEO	Nov 13 '24	Option Exercise	15.69	3,366	52,813	355,981	Nov 14 06:38 PM
Dahiyat Bassil I	PRESIDENT & CEO	Nov 13 '24	Sale	24.02	3,366	80,842	352,615	Nov 14 06:38 PM
Desjarlais John R	SR. VICE PRESIDENT & CSO	Nov 11 '24	Option Exercise	15.69	68,684	1,077,652	268,788	Nov 13 05:46 PM
Desjarlais John R	SR. VICE PRESIDENT & CSO	Nov 12 '24	Option Exercise	15.69	12,774	200,424	212,878	Nov 13 05:46 PM
Desjarlais John R	SR. VICE PRESIDENT & CSO	Nov 11 '24	Sale	23.48	68,684	1,612,639	200,104	Nov 13 05:46 PM
Dahiyat Bassil I	Officer	Nov 13 '24	Proposed Sale	24.02	3,366	80,842		Nov 13 04:21 PM
Desjarlais John R	Officer	Nov 11 '24	Proposed Sale	23.48	68,684	1,612,638		Nov 12 08:33 AM
ROSA-BJORKESON DAGMAR	Director	Sep 27 '24	Sale	20.68	2,503	51,762	8,490	Oct 01 04:13 PM
RANIERI RICHARD J	Director	Sep 27 '24	Sale	20.68	2,503	51,762	8,490	Oct 01 04:12 PM
GUSTAFSON KURT A	Director	Sep 27 '24	Sale	20.68	2,503	51,762	9,490	Oct 01 04:10 PM
GORMAN KEVIN CHARLES	Director	Sep 27 '24	Sale	20.68	2,654	54,885	8,392	Oct 01 04:09 PM
Montgomery Alan Bruce	Director	Sep 27 '24	Sale	20.68	1,853	38,320	9,140	Oct 01 04:08 PM
Feigal Ellen	Director	Sep 27 '24	Sale	20.68	2,503	51,762	8,490	Oct 01 04:07 PM
GORMAN KEVIN CHARLES	Director	Sep 27 '24	Proposed Sale	20.68	2,654	54,885		Sep 27 10:58 AM
Montgomery Alan Bruce	Director	Sep 27 '24	Proposed Sale	20.68	1,853	38,320		Sep 27 10:39 AM
Feigal Ellen	Director	Sep 27 '24	Proposed Sale	20.68	2,503	51,762		Sep 27 10:35 AM
RANIERI RICHARD J	Director	Sep 27 '24	Proposed Sale	20.68	2,503	51,762		Sep 27 10:29 AM
GUSTAFSON KURT A	Director	Sep 27 '24	Proposed Sale	20.68	2,503	51,762		Sep 27 10:12 AM
ROSA-BJORKESON DAGMAR	Director	Sep 27 '24	Proposed Sale	20.68	2,503	51,762		Sep 27 09:41 AM
Desjarlais John R	SR. VICE PRESIDENT & CSO	Jul 09 '24	Option Exercise	10.73	42,215	452,967	228,648	Jul 11 06:41 PM
Desjarlais John R	SR. VICE PRESIDENT & CSO	Jul 10 '24	Option Exercise	10.73	7,785	83,533	200,104	Jul 11 06:41 PM
Desjarlais John R	SR. VICE PRESIDENT & CSO	Jul 09 '24	Sale	18.32	36,329	665,511	192,319	Jul 11 06:41 PM
Valente Nancy	EVP, Chief Development Officer	May 02 '24	Sale	23.58	4,745	111,872	55,115	May 03 04:06 PM
Kuch John J	SR. VICE PRESIDENT & CFO	Mar 11 '24	Sale	23.50	849	19,953	121,070	Mar 12 04:08 PM
Eckert Celia	SVP, GENERAL COUNSEL	Mar 11 '24	Sale	23.50	850	19,977	45,465	Mar 12 04:06 PM
Desjarlais John R	SR. VICE PRESIDENT & CSO	Mar 11 '24	Sale	23.50	1,280	30,082	186,433	Mar 12 04:05 PM
Dahiyat Bassil I	PRESIDENT & CEO	Mar 11 '24	Sale	23.50	2,741	64,418	351,894	Mar 12 04:03 PM
GUSTAFSON KURT A	Director	Mar 06 '24	Option Exercise	10.73	15,000	160,950	20,007	Mar 07 04:10 PM
GUSTAFSON KURT A	Director	Mar 06 '24	Sale	23.18	14,000	324,453	6,007	Mar 07 04:10 PM
Kuch John J	SR. VICE PRESIDENT & CFO	Mar 05 '24	Sale	23.43	4,474	104,821	121,919	Mar 07 04:07 PM
Desjarlais John R	SR. VICE PRESIDENT & CSO	Mar 05 '24	Sale	23.43	6,629	155,311	166,989	Mar 07 04:05 PM
Eckert Celia	SVP, GENERAL COUNSEL	Mar 05 '24	Sale	23.43	3,892	91,186	33,226	Mar 07 04:03 PM
Dahiyat Bassil I	PRESIDENT & CEO	Mar 05 '24	Sale	23.43	12,528	293,519	300,097	Mar 07 04:01 PM
Desjarlais John R	SR. VICE PRESIDENT & CSO	Feb 14 '24	Option Exercise	11.05	11,943	131,970	173,618	Feb 16 04:06 PM
GORMAN KEVIN CHARLES	Director	Feb 13 '24	Buy	19.12	53	1,013	5,060	Feb 15 04:02 PM
Desjarlais John R	SR. VICE PRESIDENT & CSO	Feb 13 '24	Option Exercise	11.05	68,057	752,030	215,783	Feb 14 02:23 PM
Desjarlais John R	SR. VICE PRESIDENT & CSO	Feb 13 '24	Sale	19.38	54,108	1,048,743	161,675	Feb 14 02:23 PM
Dahiyat Bassil I	PRESIDENT & CEO	Dec 29 '23	Option Exercise	11.05	65,001	718,261	357,929	Dec 29 04:24 PM
Dahiyat Bassil I	PRESIDENT & CEO	Dec 29 '23	Sale	20.93	45,000	941,670	312,929	Dec 29 04:24 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

XNCR

Xencor Inc

Upgrade your FINVIZ experience